文献速递胸部肿瘤

系统性硬化症相关非小细胞肺癌的基因组特征:TP53突变富集与可靶向驱动基因稀少

The Genomic Landscape of NSCLC in Systemic Sclerosis Reveals Frequent TP53 Mutations and a Paucity of Actionable Oncogenes.
PubMed 文献 · J Thorac Oncol · 2025-10-21

本研究回顾性分析27例系统性硬化症(SSc)及10例其他炎症性间质性肺病(ILD)相关NSCLC患者的肿瘤基因组,并与大型NSCLC队列比较。结果显示,SSc从不/轻度吸烟者的NSCLC中经典可靶向驱动基因(EGFR/ERBB2突变及致癌融合)缺失,TP53突变富集(75% vs 45.8%,p=0.038),且APOBEC相关突变签名增加(55%增加,p=0.02),提示慢性炎症/自身免疫相关独特发病机制。

要点

  • SSc相关NSCLC从不/轻度吸烟者缺乏EGFR/ERBB2突变及致癌融合等经典驱动基因。
  • 该人群TP53突变富集(12/16,75%),显著高于非SSc对照(45.8%,p=0.038)。
  • APOBEC相关突变签名富集,提示慢性炎症/自身免疫参与肿瘤发生。

核心结论

  • SSc及其他炎症性ILD相关NSCLC,尤其在不吸烟/轻度吸烟者中,呈现可靶向驱动基因稀少、TP53突变频繁及APOBEC签名富集的独特基因组特征。
  • 上述特征提示与慢性炎症/自身免疫相关的独特发病机制,可能影响治疗策略。

研究设计与样本

  • 回顾性研究,纳入27例SSc相关NSCLC和10例其他炎症性ILD相关NSCLC患者进行肿瘤基因组分析。
  • 收集吸烟史和ILD特征等临床数据,分析基因组变异、肿瘤突变负荷和突变签名,并与大型NSCLC队列比较。

主要发现

  • ILD(主要为非特异性间质性肺炎)存在于所有SSc从不/轻度吸烟者中,但在中/重度吸烟者中相对少见(p=0.0016)。
  • SSc从不/轻度吸烟者NSCLC中经典驱动基因变异(EGFR或ERBB2突变及致癌融合)显著缺失:0/16 vs 474/1255,p=0.004。
  • 该人群TP53突变富集:12/16(75%)vs 639/1394(45.8%),p=0.038。
  • KRAS突变见于7/27例SSc患者,涵盖从不、轻度和中度吸烟史者。
  • SSc从不/轻度吸烟者NSCLC中APOBEC相关变异富集,较非SSc对照增加55%(p=0.02)。

临床怎么用

  • 对SSc相关NSCLC患者应全面进行基因组 profiling,不应仅因从不/轻度吸烟史而预期经典驱动基因阳性。
  • 治疗决策需考虑TP53突变和APOBEC签名富集所提示的独特生物学行为,可能影响靶向治疗选择。

局限性

  • 回顾性研究设计,样本量较小(SSc n=27,其他ILD n=10)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Systemic sclerosis (SSc) is a chronic connective tissue disease associated with a significantly elevated and disproportionate risk of developing NSCLC, yet the underlying molecular drivers remain poorly understood. Specifically, it is unclear how these tumors fit within the established molecular paradigms of lung cancer, particularly in relation to the patient's smoking status and its associated genomics. Here, we investigated the genomics of NSCLC in patients with SSc and other connective tissue diseases associated with interstitial lung disease (ILD). METHODS: We retrospectively identified patients with SSc (n = 27) and other inflammatory ILD-associated NSCLC (n = 10) who underwent tumor genomic profiling. We collected clinical data (smoking, ILD features) and analyzed genomic alterations, tumor mutational burden, and mutational signatures, comparing them to a large NSCLC cohort. RESULTS: ILD (mostly nonspecific interstitial pneumonia) was present in all SSc never/light smokers but relatively infrequent in moderate/heavy smokers (p = 0.0016). NSCLC in SSc never and light smokers (n = 16) demonstrated a significant lack of canonical driver alterations enriched in never-smokers (mutations in EGFR or ERBB2 and oncogenic fusions) compared with non-SSc counterparts (0/16 versus 474/1255, p = 0.004) Conversely, TP53 mutations were enriched in this population (12/16, 75% versus 639/1394, 45.8%; p = 0.038). KRAS mutations were found in seven of 27 patients and were identified in patients with never, light and moderate smoking history. NSCLC from never and light smokers with SSc had enrichment of APOBEC-attributable variants versus non-SSc controls (55% increase, p = 0.02). Similar genomic findings were noted in a cohort of NSCLC arising in patients with other inflammatory ILD. CONCLUSION: NSCLC in SSc and other inflammatory ILD, particularly in never and light smokers, displays distinct genomics: paucity of targetable drivers, frequent TP53 alterations, and APOBEC signature enrichment. This suggests a unique pathogenesis linked to chronic inflammation/autoimmunity, affecting therapeutic strategies.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Odintsov I, Hammer MM, Ricciuti B, et al. The Genomic Landscape of NSCLC in Systemic Sclerosis Reveals Frequent TP53 Mutations and a Paucity of Actionable Oncogenes. J Thorac Oncol. 2025. PMID: 41130409. doi:10.1016/j.jtho.2025.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。